Barzolvolimab cleared hives in about half of Phase 3 CSU patients by week 24, including many Xolair failures, but two anaphylaxis cases sent Celldex shares down 13% ahead of a 2027 BLA.
Newsletter
Pipeline, markets, policy, and science. Once a week.
KRAS sat on the undruggable list for decades. Silexion's SIL204 is built to silence the mutation earlier in the cell, and the Phase 2/3 program is now moving into patients.
Two-year ORIGIN 3 data show weekly atacicept flattened eGFR decline to 0.6 mL/min per year and cut kidney-progression events by 76 percent, with no dialysis or transplants on drug.
Definium's Phase 3 Panorama study met its primary endpoint in generalized anxiety disorder with a 5.1-point HAM-A gap, testing whether an active 50 µg control and zero psychotherapy can clear the FDA hurdle that broke Lykos.